L-Buthionine Sulfoximine
GCL inhibitor / Buthionine sulfoximine is an irreversible inhibitor of γ-glutamylcysteine ligase (GCL). GCL is the first enzyme of the cellular glutathione biosynthetic pathway. Dysregulation of glutathione homeostasis is involved in many diseases including cancer, diabetes, neurodegenerative disorders and HIV/AIDS.1 Most disease states involve decreased glutathione synthesis, however, in cancer, it is increased supporting cellular proliferation and protecting cancer cells. Pharmacological inhibition of GCL has been examined as a potential cancer treatment.2-4
Biochemicals & reagents
83730-53-4
1) Lu et al. (2009), Regulation of glutathione synthesis; Mol.Aspects Med. 30 42 2) Lee et al. (2008), Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine; Mol.Cell Biochem. 318 174 3) Li et al. (2016), The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine; Oncol.Lett. 11 474 4) Glasauer and Chandel (2014), Targeting antioxidants for cancer therapy; Biochem.Pharmacol. 92 90
-20°C
TARGET: Glutathione -- PATHWAY: Redox; Ferroptosis -- RESEARCH AREA: Oxidative stress; Cell death; Neuroscience -- DISEASE AREA: Cancer; DiabetesNeurodegeneration